Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Summary

The primary objective of the study is to evaluate the feasibility, efficacy and safety of an obinutuzumab containing conditioning regimen for poor risk CLL patients and patients with Richter's transformation requiring an allogeneic stem cell transplantation.

Timeline

Start

2017-11-13

Primary completion

2019-05-16

Completion

2019-06-06

Outcome

Outcome not reported

Stopped (Enrollment): “Prematurely terminated due to poor accrual”

Drugs

Indications